 immunolog studi interferon therapi chronic hbv infect identif factor respons lymphoblastoid interferon effect therapi patient chronic hepat viru infect immunolog paramet predict respons therapi human leukocyt antigen type ratio natur killer cell activ igm anti-hbc antibodi level a-induc lymphocyt prolif respons patient treatment addit mechan action interferon hepat viru clearanc ratio natur killer activ lymphocyt prolif respons wk treatment benefici respons therapi sustain clearanc hbeag serum hepat viru dna yr therapi igm anti-hbc level benefici respons therapi correl respons pretreat ratio natur killer activ lymphocyt prolif respons human leukocyt antigen patient No measur chang immunolog paramet nonrespond group signific rise ratio fall peripher number declin measur NK activ respond group chang maxim time hepat viru dna clearanc transient increas hepat inflamm